Anika Therapeutics Inc. Net Profit Margin

Net Profit Margin of ANIK for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Profit Margin growth rates and interactive chart. The net profit margin is equal to how much net income or profit is generated as a percentage of revenue. Net profit margin is the ratio of net profits (or net income) to revenues for a company. Net profit margin is typically expressed as a percentage. The net profit margin illustrates how much of each dollar in revenue collected by a company translates into profit.

Highlights and Quick Summary

  • Net Profit Margin for the quarter ending June 29, 2021 was 17.12% (a 106.76% increase compared to previous quarter)
  • Year-over-year quarterly Net Profit Margin decreased by -184.63%
  • Annual Net Profit Margin for 2020 was -18.38% (a -177.45% decrease from previous year)
  • Annual Net Profit Margin for 2019 was 23.73% (a 33.77% increase from previous year)
  • Annual Net Profit Margin for 2018 was 17.74% (a -36.76% decrease from previous year)
  • Twelve month Net Profit Margin ending June 29, 2021 was -9.28% (a -55.45% decrease compared to previous quarter)
  • Twelve month trailing Net Profit Margin increased by 177.01% year-over-year
Trailing Net Profit Margin for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
-9.28% -20.83% -18.38% -3.35%
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Profit Margin of Anika Therapeutics Inc.

Most recent Net Profit Marginof ANIK including historical data for past 10 years.

Interactive Chart of Net Profit Margin of Anika Therapeutics Inc.

Anika Therapeutics Inc. Net Profit Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 17.12% 8.28%
2020 -47.9% -20.23% -25.13% 16.37% -18.38%
2019 13.61% 30.98% 31.02% 18.23% 23.73%
2018 28.63% 28.37% 33.04% -31.44% 17.74%
2017 27.45% 25.33% 33.98% 23.49% 28.05%
2016 28.15% 34.71% 32.41% 30.94% 31.48%
2015 35.74% 35.39% 34.14% 22.65% 33.07%
2014 33.61% 27.98% 35.4% 44.19% 36.29%
2013 31.31% 27.92% 28.3% 20.12% 27.4%
2012 19.74% 11.14% 19.04% 13.31% 16.48%
2011 15.63% 16.13% 14.14% 2.76% 13.07%
2010 9.18% 7.77%

Business Profile of Anika Therapeutics Inc.

Sector: Healthcare
Industry: Medical Devices
Anika Therapeutics, Inc., together with its subsidiaries, operates as a joint preservation company that in the United States, Europe, and internationally. The company's joint pain management products include Monovisc and Orthovisc, which are single- and multi-injection, hyaluronic acid (HA)-based viscosupplements to provide pain relief from osteoarthritis (OA) conditions; Cingal, a novel, third-generation, single-injection OA product consisting of its proprietary cross-linked HA material combined with a steroid to provide short- and long-term pain relief; and Hyvisc, an injectable HA veterinary product for the treatment of joint dysfunction in horses. It also offers joint preservation and restoration products comprising preserving joint technologies, such as partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions caused by trauma, injury, and arthritic disease; soft tissue repair solutions used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma, and disease; Tactoset, an HA-enhanced injectable bone repair therapy to treat insufficiency fractures; and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. In addition, the company provides Hyalobarrier, an anti-adhesion barrier for use after abdomino-pelvic surgeries; Hyalomatrix for the treatment of complex wounds, such as burns and ulcers; products for the treatment of ears, nose, and throat disorder; and ophthalmic products, including injectables, high molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, consisting of cataract extraction and intraocular lens implantation. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.